高 RIG-I 和 EFTUD2 的表达预示着子宫内膜癌患者的预后不良。
High RIG-I and EFTUD2 expression predicts poor survival in endometrial cancer.
机构信息
Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany.
Institute of Pathology, University Hospital, LMU Munich, Munich, Germany.
出版信息
J Cancer Res Clin Oncol. 2023 Jul;149(8):4293-4303. doi: 10.1007/s00432-022-04271-z. Epub 2022 Sep 7.
PURPOSE
Endometrial cancer is the most common gynecological malignancy. The helicase RIG-I, a part of the innate immune system, and EFTUD2, a splicing factor which can upregulate RIG-I expression, are shown to influence tumor growth and disease progression in several malignancies. For endometrial cancer, an immunogenic cancer, data about RIG-I and EFTUD2 are still missing. The aim of this study was to examine the expression of RIG-I and EFTUD2 in endometrial cancer.
METHODS
225 specimen of endometrial cancer were immunohistochemically stained for RIG-I and EFTUD2. The results were correlated to clinicopathological data, overall survival (OS) and progression-free survival (PFS).
RESULTS
High RIG-I expression correlated with advanced tumor stages (FIGO: p = 0.027; pT: p = 0.010) and worse survival rates (OS: p = 0.009; PFS: p = 0.022). High EFTUD2 expression correlated to worse survival rates (OS: p = 0.026; PFS: p < 0.001) and was determined to be an independent marker for progression-free survival.
CONCLUSION
Our data suggest that the expression of RIG-I and EFTUD2 correlates with survival data, which makes both a possible therapeutic target in the future.
目的
子宫内膜癌是最常见的妇科恶性肿瘤。作为先天免疫系统的一部分，解旋酶 RIG-I 和剪接因子 EFTUD2 可以上调 RIG-I 的表达，它们在几种恶性肿瘤中影响肿瘤生长和疾病进展。对于子宫内膜癌这种免疫原性癌症，有关 RIG-I 和 EFTUD2 的数据仍然缺乏。本研究旨在研究 RIG-I 和 EFTUD2 在子宫内膜癌中的表达。
方法
对 225 例子宫内膜癌标本进行 RIG-I 和 EFTUD2 的免疫组织化学染色。将结果与临床病理数据、总生存期 (OS) 和无进展生存期 (PFS) 相关联。
结果
高 RIG-I 表达与晚期肿瘤分期（FIGO：p=0.027；pT：p=0.010）和较差的生存率相关（OS：p=0.009；PFS：p=0.022）。高 EFTUD2 表达与较差的生存率相关（OS：p=0.026；PFS：p<0.001），并被确定为无进展生存期的独立标志物。
结论
我们的数据表明，RIG-I 和 EFTUD2 的表达与生存数据相关，这使得它们成为未来可能的治疗靶点。
Zotero 插件